Vericel Corp (VCEL) stock
VCELNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 16/30254% above fair value
$57.42−2.03 (-3.41%)
Close on Nov 12, 2026Market cap $2.94BP/E 97.3Yield –
Vericel operating margin
Operating margin is operating income as a percentage of revenue.
Vericel's operating margin for the twelve months ending Sep 30, 2026 was 8.3%. For fiscal 2025 it was 4.0%, against 1.9% the year before. The highest annual figure on record is 4.0% in fiscal 2025.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4.0% | +2.1 |
| FY2024 | Dec 31, 2024 | 1.9% | +5.2 |
| FY2023 | Dec 31, 2023 | -3.3% | +7.1 |
| FY2022 | Dec 31, 2022 | -10.4% | −5.3 |
| FY2021 | Dec 31, 2021 | -5.0% | −6.9 |
| FY2020 | Dec 31, 2020 | 1.9% | +11.5 |
| FY2019 | Dec 31, 2019 | -9.5% | −5.2 |
| FY2018 | Dec 31, 2018 | -4.3% | +19.1 |
| FY2017 | Dec 31, 2017 | -23.4% | +11.9 |
| FY2016 | Dec 31, 2016 | -35.4% | −2.8 |
| FY2015 | Dec 31, 2015 | -32.6% | +49.1 |
| FY2014 | Dec 31, 2014 | -81.7% | +110255.1 |
| FY2013 | Dec 31, 2013 | -110336.8% | +50425.1 |
| FY2012 | Dec 31, 2012 | -160761.9% | −140757.4 |
| FY2010 | Jun 30, 2010 | -20004.5% | −11120.4 |
| FY2009 | Jun 30, 2009 | -8884.1% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 14.3% | +9.2 |
| Q2 FY2026 | Jun 30, 2026 | 0.6% | +3.8 |
| Q1 FY2026 | Mar 31, 2026 | -11.8% | +12.5 |
| Q4 FY2025 | Dec 31, 2025 | 24.1% | −0.4 |
| Q3 FY2025 | Sep 30, 2025 | 5.1% | +9.4 |
| Q2 FY2025 | Jun 30, 2025 | -3.2% | +8.2 |
| Q1 FY2025 | Mar 31, 2025 | -24.3% | −13.7 |
| Q4 FY2024 | Dec 31, 2024 | 24.5% | +4.9 |
| Q3 FY2024 | Sep 30, 2024 | -4.3% | +6.8 |
| Q2 FY2024 | Jun 30, 2024 | -11.5% | +1.5 |
| Q1 FY2024 | Mar 31, 2024 | -10.7% | +9.3 |
| Q4 FY2023 | Dec 31, 2023 | 19.6% | +8.0 |
| Q3 FY2023 | Sep 30, 2023 | -11.1% | +6.5 |
| Q2 FY2023 | Jun 30, 2023 | -13.0% | +11.5 |
| Q1 FY2023 | Mar 31, 2023 | -19.9% | +0.2 |
| Q4 FY2022 | Dec 31, 2022 | 11.5% | +2.8 |
| Q3 FY2022 | Sep 30, 2022 | -17.6% | −3.2 |
| Q2 FY2022 | Jun 30, 2022 | -24.5% | −15.1 |
| Q1 FY2022 | Mar 31, 2022 | -20.2% | −10.6 |
| Q4 FY2021 | Dec 31, 2021 | 8.7% | −18.5 |
| Q3 FY2021 | Sep 30, 2021 | -14.4% | −25.3 |
| Q2 FY2021 | Jun 30, 2021 | -9.4% | +32.3 |
| Q1 FY2021 | Mar 31, 2021 | -9.6% | +9.5 |
| Q4 FY2020 | Dec 31, 2020 | 27.2% | +3.8 |
| Q3 FY2020 | Sep 30, 2020 | 10.9% | +0.7 |
| Q2 FY2020 | Jun 30, 2020 | -41.8% | +35.5 |
| Q1 FY2020 | Mar 31, 2020 | -19.0% | −3.6 |
| Q4 FY2019 | Dec 31, 2019 | 23.4% | +4.2 |
| Q3 FY2019 | Sep 30, 2019 | 10.2% | +16.1 |
| Q2 FY2019 | Jun 30, 2019 | -77.2% | −54.9 |
| Q1 FY2019 | Mar 31, 2019 | -15.4% | +8.6 |
| Q4 FY2018 | Dec 31, 2018 | 19.1% | +14.0 |
| Q3 FY2018 | Sep 30, 2018 | -5.9% | +22.3 |
| Q2 FY2018 | Jun 30, 2018 | -22.3% | −7.5 |
| Q1 FY2018 | Mar 31, 2018 | -24.0% | +78.8 |
| Q4 FY2017 | Dec 31, 2017 | 5.1% | +0.0 |
| Q3 FY2017 | Sep 30, 2017 | -28.3% | – |
| Q2 FY2017 | Jun 30, 2017 | -14.9% | – |
| Q1 FY2017 | Mar 31, 2017 | -102.8% | – |
| Q4 FY2016 | Dec 31, 2016 | 5.1% | – |
See a number that looks wrong?